We recently published 12 Stocks on Jim Cramer’s Radar.  Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer's radar. Healthcare giant Johnson & Johnson (NYSE:JNJ) factored into the discussion after Cramer and his co-hosts discussed Pfizer and Merck. The firm’s shares are up by 46% year-to-date and have had a good December so far. During this time period, Johnson & Johnson (NYSE:JNJ) has reported several important developments. For instance, the firm announced on December 12th that it had secur ...

公司评级与目标价 - H C Wainwright分析师Mitchell Kapoor维持买入评级 目标价为90美元 [1] 临床试验进展与影响 - MajesTEC-3试验结果显示在无进展生存期和总生存期方面相比现有疗法有显著改善 [2] - 该试验将强生的DARZALEX Faspro与TECVAYLI联合使用 试验结果增强了公司基于DARZALEX方案的证据 [3] - DARZALEX Faspro采用公司的ENHANZE技术 试验成功有助于提升公司的特许权使用费基础 [3] 公司业务与技术平台 - 公司是一家生物制药技术平台公司 致力于通过先进的自动注射器技术开发、制造和商业化药物器械组合产品 [4] - 公司产品具有商业和功能优势 包括提高患者舒适度和依从性 以及增强耐受性和便利性 [4]